MIM
INBX icon

MetLife Investment Management’s Inhibrx INBX Stock Holding History

MetLife Investment Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Sell
5,240
-80
-2% -$5.93K ﹤0.01% 1923
2025
Q4 		$420K Sell
5,320
-2,105
-28% -$143K ﹤0.01% 1874
2025
Q3 		$250K Sell
7,425
-258
-3% -$6.35K ﹤0.01% 2192
2025
Q2 		$110K Hold
7,683
– – ﹤0.01% 2496
2025
Q1 		$107K Hold
7,683
– – ﹤0.01% 2492
2024
Q4 		$118K Buy
7,683
+1,826
+31% +$27.8K ﹤0.01% 2544
2024
Q3 		$91.7K Buy
5,857
+1,034
+21% +$14.5K ﹤0.01% 2660
2024
Q2 		$68.3K Buy
+4,823
New +$75.3K ﹤0.01% 2711

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MetLife Investment Management's INBX Position: Q1 2026 in Review

MetLife Investment Management reduced its Inhibrx (INBX) stake by 1.5% in Q1 2026, selling an estimated $5.93K and leaving 5,240 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #1923.

MetLife Investment Management first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $420K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • MetLife Investment Management held 5,240 shares of Inhibrx worth $352K as of Q1 2026.
  • MetLife Investment Management sold 80 Inhibrx shares in Q1 2026, an estimated $5.93K.
  • Inhibrx made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1923 holding.
  • MetLife Investment Management first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • MetLife Investment Management's Inhibrx position peaked at $420K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.